Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
J Immunother Cancer
; 8(2)2020 07.
Artículo
en Inglés
| MEDLINE | ID: covidwho-662488
ABSTRACT
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía
/
Neumonía Viral
/
Infecciones por Coronavirus
/
Antineoplásicos Inmunológicos
/
Neoplasias
Tipo de estudio:
Estudios diagnósticos
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Jitc-2020-000952
Similares
MEDLINE
...
LILACS
LIS